About Zinc finger protein 480
Zinc finger protein 480 (ZNF480) is a protein
from Homo sapiens identified by UniProt accession
Q8WV37, 535 residues long.
MolForge cross-references it against 0 known binders and
14 disease associations.
Target properties
| Protein name | Zinc finger protein 480 |
| UniProt accession | Q8WV37 |
| Gene | ZNF480 |
| Organism | Homo sapiens |
| Length | 535 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (14)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.34
- quadriplegia · score 0.07
- neoplasm · score 0.03
- type 2 diabetes mellitus · score 0.03
- schizophrenia · score 0.01
- cancer · score 0.01
- anaplastic oligodendroglioma · score 0.00
- Dorfman-Chanarin disease · score 0.00
- anaplastic astrocytoma · score 0.00
- non-alcoholic steatohepatitis · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8WV37-F1 | alphafold | PREDICTED | 70.39 | — |
Amino-acid sequence (535 residues)
MLCDEKAQKR RKRKAKESGM ALPQGHLTFR DVAIEFSQAE WKCLDPAQRA LYKDVMLENY RNLVSLGISL PDLNINSMLE QRREPWSGES EVKIAKNSDG RECIKGVNTG SSYALGSNAE DKPIKKQLGV SFHLHLSELE LFPDERVING CNQVENFINH SSSVSCLQEM SSSVKTPIFN RNDFDDSSFL PQEQKVHLRE KPYECNEHSK VFRVSSSLTK HQVIHTVEKP YKCNSCGKVF SRNSHLAEHC RIHTGEKPYK CNVCGKVFSY NSNFARHQRI HTREKPYECN ECGKVFSNNS YLARHQRIHA EEKPYKCNEC GKGFSHKSSL ANHWRIYTGE KPYKCDECGK AFYRIALLVR HQKIHTGEKP YKCNECGKVF IQNSHLAQHW RIHTGEKPYK CNECGKVFNQ LSNLARHRRI HTGEKPYKCN ECGKAFSEYS GLSAHLVIHT GEKPYKCSEC GKAFRHKLSL TNHQRIHTGE RPYKCNECGK VFNRIAHLAR HRKIHTGEKP YKCNECGKAF SRISYLAQHW TIHMG
Explore Zinc finger protein 480 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets